經(jīng)顱多普勒超聲輔助巴曲酶治療對預(yù)防進展性缺血性腦卒中作用的多因素分析
發(fā)布時間：2019-07-01 10:50
【摘要】：目的探討在靜脈應(yīng)用巴曲酶的同時應(yīng)用經(jīng)顱多普勒超聲(TCD)連續(xù)監(jiān)測責(zé)任血管,是否可通過其超聲波的理化效應(yīng)增強巴曲酶預(yù)防進展性缺血性腦卒中(PIS)的療效。方法 100例連續(xù)納入急性腦梗死患者隨機分為對照組和觀察組,每組50例。對照組患者接受急性腦梗死常規(guī)治療及靜脈巴曲酶治療,觀察組患者在此基礎(chǔ)上在巴曲酶治療時應(yīng)用TCD連續(xù)監(jiān)測責(zé)任血管。除去失訪患者,最終對照組47例及觀察組43例患者納入統(tǒng)計。比較兩組患者治療前的基線特征、治療后3 d的血纖維蛋白原值、治療后1周的美國國立衛(wèi)生研究院卒中量表(NIHSS)評分及PIS發(fā)生率;最后應(yīng)用多因素分析探討在靜脈應(yīng)用巴曲酶的同時使用TCD連續(xù)監(jiān)測責(zé)任血管是否是預(yù)防PIS發(fā)生的獨立影響因素。結(jié)果兩組患者基線特征差異無統(tǒng)計學(xué)意義,觀察組治療后1周的血纖維蛋白原值、NIHSS評分、1周內(nèi)PIS發(fā)生率均顯著低于對照組(P=0.033、0.002、0.049);經(jīng)二元logistic回歸分析,在靜脈應(yīng)用巴曲酶的同時使用TCD連續(xù)監(jiān)測責(zé)任血管是預(yù)防PIS發(fā)生的獨立影響因素。結(jié)論對于急性腦梗死患者,在靜脈應(yīng)用巴曲酶治療的同時使用TCD對責(zé)任腦血管連續(xù)監(jiān)測1 h能夠增強巴曲酶的降纖作用,有效減少PIS發(fā)生。
[Abstract]:Objective to investigate whether batroxobin can enhance the efficacy of batroxobin in the prevention of progressive ischemic stroke (PIS) by continuously monitoring the responsible vessels by transcranial Doppler ultrasound (TCD) in conjunction with the intravenous application of batroxobin. Methods 100 patients with acute cerebral infarction were randomly divided into control group (n = 50) and observation group (n = 50). The patients in the control group were treated with routine treatment of acute cerebral infarction and intravenous batroxobin. On this basis, the patients in the observation group were treated with TCD for continuous monitoring of responsible vessels. Except for the lost patients, 47 patients in the control group and 43 patients in the observation group were included in the statistics. The baseline characteristics before treatment, the blood fibrin value 3 days after treatment, the (NIHSS) score and the incidence of PIS in the National Institutes of Health Stroke scale 1 week after treatment were compared between the two groups. Finally, multivariate analysis was used to explore whether the continuous monitoring of responsible vessels with batroxobin and TCD was an independent factor to prevent the occurrence of PIS. Results there was no significant difference in the baseline characteristics between the two groups. The blood fibrin value, NIHSS score and the incidence of PIS within 1 week in the observation group were significantly lower than those in the control group (P 鈮，
本文編號：2508414
[Abstract]:Objective to investigate whether batroxobin can enhance the efficacy of batroxobin in the prevention of progressive ischemic stroke (PIS) by continuously monitoring the responsible vessels by transcranial Doppler ultrasound (TCD) in conjunction with the intravenous application of batroxobin. Methods 100 patients with acute cerebral infarction were randomly divided into control group (n = 50) and observation group (n = 50). The patients in the control group were treated with routine treatment of acute cerebral infarction and intravenous batroxobin. On this basis, the patients in the observation group were treated with TCD for continuous monitoring of responsible vessels. Except for the lost patients, 47 patients in the control group and 43 patients in the observation group were included in the statistics. The baseline characteristics before treatment, the blood fibrin value 3 days after treatment, the (NIHSS) score and the incidence of PIS in the National Institutes of Health Stroke scale 1 week after treatment were compared between the two groups. Finally, multivariate analysis was used to explore whether the continuous monitoring of responsible vessels with batroxobin and TCD was an independent factor to prevent the occurrence of PIS. Results there was no significant difference in the baseline characteristics between the two groups. The blood fibrin value, NIHSS score and the incidence of PIS within 1 week in the observation group were significantly lower than those in the control group (P 鈮，
本文編號：2508414
本文鏈接：http://sikaile.net/yixuelunwen/shenjingyixue/2508414.html
最近更新
教材專著
